XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinsonís disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.